Suppression of established Eμ-myc tumor growth in mice treated with α-GalCer–loaded tumor vaccine. WT mice were challenged with 1 × 105 GFP-expressing Eμ-myc 299 tumor cells (A-C) or 1 × 105 luciferase-expressing Eμ-myc 4242 tumor cells (D-F) and 5 days later treated with a single administration of irradiated, unloaded, or α-GalCer–loaded autologous Eμ-myc tumor cells. (A) Representative flow cytometry plots showing 299 tumor burden (gated B220+GFP+ cell population) at day 19 in blood. (B) Data are mean ± SEM (n = 5) 299 tumor burden in blood of WT mice after vaccine treatment. ***P < .001 (unpaired t test). (C) Overall survival of mice (n = 5) receiving unloaded or α-GalCer–loaded 299 tumor vaccine on day 5. **P = .002 (log-rank test). (D) Representative in vivo bioluminescent images of Eμ-myc 4242 tumor burden (luciferase activity) in untreated (top panels) or vaccine-treated (bottom panels) mice at 14 days after tumor inoculation. (E) Data are mean ± SEM (n = 5) bioluminescent photon counts of total 4242 tumor burden in the whole mouse quantified from live bioluminescent imaging as in panel A. **P < .005 (unpaired t test). *P < .05 (unpaired t test). (F) Overall survival of untreated or vaccine-treated mice (n = 5). #P = .004 (log-rank test). Arrows indicate day of vaccination. Three independent experiments were performed.
